Tamoxifen is a drug that is often used to treat breast cancer
116 patients with platinum-sensitive ovarian cancer presenting an isolated increase of CA-125 were planned to be randomized
Judson PL, et
Ovarian cancer is classified as hormonal dependent cancer
Patients and methods: A retrospective review was conducted of patients
• There is an unmet medical need for asymptomatic patients with CA-125 increase
reviewed 14 studies of tamoxifen for ovarian cancer and reported an overall objective response rate of 10% (range, 0-56%) and a stable disease rate of 32% Several researchers have also investigated gonadotropin-releasing analogues for the treatment of recurrent ovarian cancer [19,33,34]
Indoleamine 2,3-dioxygenase-1 (IDO1) is a key regulator of immune tolerance in ovarian cancer
Until recently, most women who received adjuvant hormone therapy to reduce the chance of a breast cancer recurrence took tamoxifen every day for 5 years
SOURCES: American Cancer Society: “Hormone Therapy,” “Hormone Therapy for Ovarian Cancer
Introduction
[36,37] Unfortunately, EBCTCG analyses of tamoxifen conducted in 1990 and reported in 1992 showed only a modest effect of tamoxifen on recurrence and no effect on mortality for women below the age of 50 years
Tamoxifen has changed the landscape of breast cancer treatment and prevention since its introduction in the late 1960’s
This review examines the evidence for useful clinical activity of tamoxifen in women with ovarian carcinoma who have failed conventional cytotoxic chemotherapy
Objectives
This study investigated efficacy and safety of the IDO1 enzyme inhibitor epacadostat versus tamoxifen in patients with biochemical-only recurrence (CA-125 elevation) following complete remission after first-line chemotherapy for advanced